Mrs. Lamyaa Bakoss is a pharmacist who is specialized in Oncology in Brooklyn, New York. Patients can reach her at 428 Ovington Ave, 2e, Brooklyn or contact her on 718-780-5962. Active license number of Mrs. Lamyaa Bakoss is 047004 for Oncology in New York. Mrs. Lamyaa Bakoss is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Mrs. Lamyaa Bakoss speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Mrs. Lamyaa Bakoss
Specialization:
Oncology
Credentials:
RPH
Gender:
Female
Location:
428 Ovington Ave, 2e, Brooklyn, New York, 11209-1551
Phone:
718-780-5962
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Mrs. Lamyaa Bakoss are as mentioned below.
NPI Number:
1831245604
NPI Enumeration Date:
26 Jan, 2007
NPI Last Update On:
18 Jan, 2022
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Mrs. Lamyaa Bakoss are as mentioned below.
Specialization
License Number
State
Status
Oncology
047004
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
428 Ovington Ave, 2e Brooklyn, New York
Zip:
11209-1551
Phone Number:
718-780-5962
Fax Number:
--
Patients can reach Mrs. Lamyaa Bakoss at 428 Ovington Ave, 2e, Brooklyn, New York or can call on phone at 718-780-5962.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.